JP2022545920A5 - - Google Patents

Info

Publication number
JP2022545920A5
JP2022545920A5 JP2022513208A JP2022513208A JP2022545920A5 JP 2022545920 A5 JP2022545920 A5 JP 2022545920A5 JP 2022513208 A JP2022513208 A JP 2022513208A JP 2022513208 A JP2022513208 A JP 2022513208A JP 2022545920 A5 JP2022545920 A5 JP 2022545920A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
single dose
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048649 external-priority patent/WO2021042000A1/en
Publication of JP2022545920A publication Critical patent/JP2022545920A/ja
Publication of JP2022545920A5 publication Critical patent/JP2022545920A5/ja
Priority to JP2025129247A priority Critical patent/JP2025185263A/ja
Pending legal-status Critical Current

Links

JP2022513208A 2019-08-29 2020-08-28 B型肝炎ウイルス感染を処置するための抗体組成物および方法 Pending JP2022545920A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025129247A JP2025185263A (ja) 2019-08-29 2025-08-01 B型肝炎ウイルス感染を処置するための抗体組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893742P 2019-08-29 2019-08-29
US62/893,742 2019-08-29
PCT/US2020/048649 WO2021042000A1 (en) 2019-08-29 2020-08-28 Antibody compositions and methods for treating hepatitis b virus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025129247A Division JP2025185263A (ja) 2019-08-29 2025-08-01 B型肝炎ウイルス感染を処置するための抗体組成物および方法

Publications (2)

Publication Number Publication Date
JP2022545920A JP2022545920A (ja) 2022-11-01
JP2022545920A5 true JP2022545920A5 (cg-RX-API-DMAC7.html) 2023-08-31

Family

ID=72473989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513208A Pending JP2022545920A (ja) 2019-08-29 2020-08-28 B型肝炎ウイルス感染を処置するための抗体組成物および方法
JP2025129247A Pending JP2025185263A (ja) 2019-08-29 2025-08-01 B型肝炎ウイルス感染を処置するための抗体組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025129247A Pending JP2025185263A (ja) 2019-08-29 2025-08-01 B型肝炎ウイルス感染を処置するための抗体組成物および方法

Country Status (11)

Country Link
US (2) US20220380441A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021578A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022545920A (cg-RX-API-DMAC7.html)
KR (1) KR20220063188A (cg-RX-API-DMAC7.html)
CN (1) CN114630680B (cg-RX-API-DMAC7.html)
AU (1) AU2020336980B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003698A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152511A1 (cg-RX-API-DMAC7.html)
IL (1) IL290923A (cg-RX-API-DMAC7.html)
MX (1) MX2022002231A (cg-RX-API-DMAC7.html)
WO (1) WO2021042000A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3898668T1 (sl) 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
PT4285929T (pt) 2018-12-20 2026-01-02 Humabs Biomed Sa Terapêutica de combinação contra o vhb
JP2024504167A (ja) * 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド B型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2023230439A1 (en) * 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
EA202091521A1 (ru) * 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
SI3898668T1 (sl) * 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
PT4285929T (pt) * 2018-12-20 2026-01-02 Humabs Biomed Sa Terapêutica de combinação contra o vhb

Similar Documents

Publication Publication Date Title
Lok Treatment of chronic hepatitis B
Qaqish et al. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection
JP2022532211A5 (cg-RX-API-DMAC7.html)
JP2018512428A5 (cg-RX-API-DMAC7.html)
CN115920061A (zh) Hbv和hdv感染的联合治疗
KR20220098345A (ko) 바이러스성 간염을 치료 또는 예방하기 위한 약물 조성물 및 그의 응용
KR20220119616A (ko) Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법
RS61944B1 (sr) Lečenje infekcije hepatitis delta virusom sa interferonom lambda
JP2025511096A5 (cg-RX-API-DMAC7.html)
Kim et al. Telbivudine: a novel nucleoside analog for chronic hepatitis B
Lau Hepatitis B infection in China
JP2002534438A (ja) 新規治療法
AU2020314081B2 (en) Synergistic effect of EYP001 and IFN for the treatment of HBV infection
NZ785788B2 (en) Antibody compositions and methods for treating hepatitis b virus infection
NZ785788A (en) Antibody compositions and methods for treating hepatitis b virus infection
KR20120125253A (ko) B형 간염 바이러스 감염 치료용 조성물 및 치료방법
Zuccotti et al. A 1-year trial of lamivudine for chronic hepatitis B in children
Çakir et al. Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations
WO2008104133A1 (es) Terapia combinada para el tratamiento de la hepatitis b crónica
CN112891510A (zh) 采用iap抑制剂的治疗方法
HK40044248A (en) Treatment method with iap inhibitor
HK40088755A (en) Combination therapy of hbv and hdv infection
Korkmaz et al. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
EA046230B1 (ru) Синергическое действие eyp001 и ifn при лечении инфекции hbv
HK40066536B (en) Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection